The British medical journal Lancet has published some startling – but welcome – news. A clinical trial of a high-risk treatment for multiple sclerosis (MS) was so successful with some patients that researchers are daring to mention the word “cure.”
The British medical journal Lancet has published some startling – but welcome – news. A clinical trial of a high-risk treatment for multiple sclerosis (MS) was so successful with some patients that researchers are daring to mention the word “cure.”
Follow us on